1. Home
  2. IKNA vs VTSI Comparison

IKNA vs VTSI Comparison

Compare IKNA & VTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • VTSI
  • Stock Information
  • Founded
  • IKNA 2016
  • VTSI 1993
  • Country
  • IKNA United States
  • VTSI United States
  • Employees
  • IKNA N/A
  • VTSI N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • VTSI Miscellaneous manufacturing industries
  • Sector
  • IKNA Health Care
  • VTSI Consumer Discretionary
  • Exchange
  • IKNA Nasdaq
  • VTSI Nasdaq
  • Market Cap
  • IKNA 61.8M
  • VTSI 45.2M
  • IPO Year
  • IKNA 2021
  • VTSI N/A
  • Fundamental
  • Price
  • IKNA $1.08
  • VTSI $4.60
  • Analyst Decision
  • IKNA Buy
  • VTSI Strong Buy
  • Analyst Count
  • IKNA 2
  • VTSI 2
  • Target Price
  • IKNA $3.00
  • VTSI $13.00
  • AVG Volume (30 Days)
  • IKNA 95.3K
  • VTSI 67.1K
  • Earning Date
  • IKNA 05-20-2025
  • VTSI 05-12-2025
  • Dividend Yield
  • IKNA N/A
  • VTSI N/A
  • EPS Growth
  • IKNA N/A
  • VTSI N/A
  • EPS
  • IKNA N/A
  • VTSI 0.12
  • Revenue
  • IKNA N/A
  • VTSI $26,350,819.00
  • Revenue This Year
  • IKNA N/A
  • VTSI N/A
  • Revenue Next Year
  • IKNA N/A
  • VTSI $22.35
  • P/E Ratio
  • IKNA N/A
  • VTSI $37.08
  • Revenue Growth
  • IKNA N/A
  • VTSI N/A
  • 52 Week Low
  • IKNA $0.97
  • VTSI $3.57
  • 52 Week High
  • IKNA $1.94
  • VTSI $17.68
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 37.62
  • VTSI 54.70
  • Support Level
  • IKNA $1.22
  • VTSI $4.23
  • Resistance Level
  • IKNA $1.29
  • VTSI $4.61
  • Average True Range (ATR)
  • IKNA 0.09
  • VTSI 0.32
  • MACD
  • IKNA -0.01
  • VTSI 0.10
  • Stochastic Oscillator
  • IKNA 1.75
  • VTSI 77.44

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About VTSI VirTra Inc.

VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.

Share on Social Networks: